In RKO tumor-bearing mice, TAVO423 demonstrated a superior antitumor effect (TGI = 57%) compared to PD-L1 × HYAL (TGI = 26%) when administered at the same dose (Figure 4B). The gene discussed is CD274; the disease is neoplasm.